Synthetic biology may open up a number of manufacturing possibilities, but there are still obstacles to overcome, according to Nature News.
The deal is the latest partnership to provide exposure for Cambridge, Massachusetts-based Gen9's BioFab gene synthesis platform.
Wired examines Twist Bioscience's approach to synthesizing DNA.
The startup bioinformatics firm has integrated its algorithms with Gen9's synthetic DNA manufacturing process and is expanding its digital lab notebook.
Sorting out which agency regulates what synthetic biology creation is a source of confusion for the field, a new report says.
The Foundry is developing genetic engineering technology that can be applied on a scale not possible with current methods.
J. Craig Venter tells the WorldPost that humans now have the ability to control evolution, though perhaps not yet the wisdom to do it safely.
As newly-minted GenoFAB mulls commercial models for its GenoCAD DNA design web app, the company is trying to engage with its target market through pilot projects.
Gen9 will make new versions of DNA parts for use by iGEM collaborators, including participants in the non-profit's annual student competition.
In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.